Unknown OBSERVATIONAL NCT00188084

Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia

Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial

Sponsor: French Innovative Leukemia Organisation

Conditions Adult Acute Lymphoblastic Leukemia

Interventions CD45 expression DNA Index P16 metabolic way S-Phase%

Updated 6 times since 2017 Last updated: Oct 27, 2005 Started: Nov 30, 2003 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00188084, this observational or N/A phase trial focuses on Adult Acute Lymphoblastic Leukemia and remains ongoing. Sponsored by French Innovative Leukemia Organisation, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Jun 2018 — Jan 2021 [monthly]

Unknown Status
Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Unknown Status NA

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

French Innovative Leukemia Organisation
University Hospital, Angers

Data source: University Hospital, Angers

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Angers, France